ZBTB21 Recombinant Rabbit mAb (S-3936-49)

ZBTB21 (Zinc Finger and BTB Domain-Containing Protein 21, also known as ZNF295) is a ubiquitously expressed transcriptional repressor in humans. Its protein structure features an N-terminal BTB/POZ domain, which mediates protein dimerization and interactions with transcriptional co-repressor complexes, as well as multiple C2H2-type zinc finger domains responsible for sequence-specific DNA binding. As a critical node in epigenetic regulation, ZBTB21 restricts STAT1-mediated chromatin accessibility by reducing H3K27ac histone modifications, thereby epigenetically silencing GSDMD-dependent pyroptosis. Simultaneously, it suppresses tumor cell surface MHC-I antigen presentation by attenuating IRF1 expression and its transcriptional activation capacity. This dual inhibitory mechanism makes ZBTB21 a major driver of tumor immune evasion. Notably, recent studies have demonstrated that pharmacological inhibition of ZBTB21 with dobutamine or genetic knockout of ZBTB21 can simultaneously relieve the suppression of both pyroptosis and antigen presentation, significantly enhancing CD8⁺ T cell anti-tumor immune responses and exhibiting synergistic effects with anti-PD-1 immunotherapy, positioning ZBTB21 as a promising novel therapeutic target for cancer treatment.